Comprising data from a randomized comparative effectiveness trial with 329 participants from three U.S. health networks. It compares two 8-week digital behavioral treatments for chronic pain, one using a standard screen and the other using virtual reality, with surveys measuring pain intensity and distress. The study was conducted during and after the COVID-19 pandemic.
Use Cases
- Compare numeric pain score ratings between the VR and standard screen treatment arms at week 8.
- Analyze the relationship between COVID-related anxiety survey responses and pain intensity scores over the 8-week intervention.
- Assess coping skill use from the Week 12 survey data, comparing outcomes between the two digital therapy programs.
- Examine participant retention rates, comparing the 77.6% ITT analysis rate in the painTRAINER arm to the 91.1% rate in the VR arm.
Strengths
- Data from a randomized trial with 329 analyzed participants, providing a structured comparison.
- Includes validated clinical scales such as PROMIS-PI for pain intensity and measures of COVID-related anxiety.
- Participants were recruited from three major U.S. health networks, offering a multi-site perspective.
Limitations
- Sample size of 329 may limit statistical power for subgroup analyses or detecting smaller effect sizes.
- Study population is limited to English-speaking adults in U.S. rural ZIP codes, reducing generalizability to urban or non-English speaking populations.
- Relies on self-reported survey data for primary outcomes, which can be subject to recall and reporting biases.
Provenance
- Source
- ClinicalTrials.gov (NCT04933474), authored by Brennan Spiegel, ICPSR Harvested Dataverse.
- Collection Method
- Randomized comparative effectiveness trial with participants recruited from patient lists of three health networks.
- Time Range
- Study conducted during and after the COVID-19 pandemic, with data collected over 12 weeks (8-week intervention + 4-week follow-up).
- Freshness
- Last updated 2026-02-23.
- Geography
- U.S. rural ZIP codes as defined by the Federal Office of Rural Health Policy (RUCA 4–10).